Strain Provenance · Manufacturing · Verified Testing
Most probiotics differ only by the label. Maxilin differs by the organism itself, by a patented production method, and by a documentary record that can be checked independently. Here is exactly what separates it — and what still needs to be studied.
A probiotic is only as specific as its strain designation. "Lactobacillus acidophilus" names a species containing thousands of distinct strains that behave differently. Maxilin names the strain.
Maxilin is built on Lactobacillus acidophilus strain 2585, referenced in the source documents as culture 2585-1666. Strain-level identity is what allows a body of research to be attributed to one organism rather than to a species in general.
Eurasian Patent No. 014227 B1 — "Method for producing the fermented-milk product 'Maxilin' and method of correcting microflora in the organism of humans and animals" — was filed 15 December 2006 and granted 29 October 2010, valid across nine Eurasian convention states. Kazakhstan National Patent No. 14850 was filed 19 March 2004.
A patent establishes novelty and ownership. It does not, on its own, establish clinical efficacy — and it is presented here as intellectual-property history, not as proof of a health outcome.
Company lineage material describes the original organism as isolated from lamb abomasum content and newborn meconium, rather than selected for ease of laboratory cultivation. This detail comes from company historical narrative rather than from a laboratory isolation record, and is presented as such.
The 1993/1994 Ministry-approved clinical-use instructions describe strain 2585 as retaining viability and antagonistic activity under exposure to streptomycin, neomycin, monomycin, chloramphenicol (levomycetin) and gentamicin. Most probiotic organisms are themselves antibiotic-sensitive and are dosed away from an antibiotic course for that reason.
This describes a property of the organism. It is not evidence that Maxilin replaces antibiotics or treats antibiotic-resistant infection.
Getting live bacteria into a sachet is straightforward. Keeping them alive on a shelf, and then alive through gastric acid, is the part most products lose. BIODEP addresses each of those two problems with a separate industrial step.
BIODEP takes the live Lactobacillus acidophilus (strain 2585) culture after liquid fermentation and subjects it to rapid industrial freeze-drying. This process removes moisture under a vacuum, turning the liquid bacteria into a highly concentrated, shelf-stable dry powder without killing the live cells.
Because the water is drawn off as vapour directly from the frozen state, the cells are never exposed to the heat or the liquid-phase transition that would otherwise destroy them. The result is a dormant, viable culture that keeps without refrigeration.
Once dried, BIODEP applies its proprietary multi-layer embedded micro-coating technology (ProCap™) to the powder. This microscopic outer shield insulates the individual bacterial cells, ensuring they can withstand ambient moisture and survive the highly acidic passage through the human stomach.
Coating each cell individually — rather than coating a capsule that holds them — means the protection travels with the organism all the way to the intestine, which is where an acidophilus strain has to arrive intact to be of any use.
Strain 2585 is common to both forms, and the patented process and organism lineage connect them. The distinction matters when you read the evidence, because the historical record was generated on the liquid.
| Fermented liquid | Dry sachet | |
|---|---|---|
| Core organism | L. acidophilus strain 2585 | L. acidophilus strain 2585, 15 billion CFU |
| Additional organisms | Single-strain preparation | S. thermophilus 4 billion CFU; L. helveticus 1 billion CFU |
| Total viable count (label specification) | Per batch; assayed at 20 billion CFU lactic-acid microorganisms, ATU Test Report No. 798 (2024) | 20 billion CFU (company specification) |
| Also contains | Fermented-milk matrix, inulin | Resistant dextrin, inulin, vitamin C, lactase, vanillin |
| Stability | Refrigerated, short shelf life | Shelf-stable — lyophilised and ProCap™ microencapsulated |
| Where the historical evidence sits | ✓ Sections 4–9 of the physician dossier were generated on this form | Same foundational strain; independent identity, purity and viable-CFU testing of the sachet is the stated next step |
The comparison below is drawn from the documentary record rather than from marketing claims, and it is deliberately specific about where Maxilin's record is stronger and where it is not.
| Point of difference | Maxilin | Typical commercial probiotic |
|---|---|---|
| Strain identified to strain level | ✓ Strain 2585, named in patents and clinical records | Often species-level only ("L. acidophilus") |
| Patent protection on the production method | ✓ Eurasian 014227 B1; Kazakhstan 14850 | Usually none |
| Behaviour under antibiotic exposure | ✓ Tolerance documented in Ministry-approved instructions | Typically antibiotic-sensitive; dosed apart from a course |
| Indexed, independently searchable publication | ✓ PMID 10961107 (Stomatologiia, 2000) | Varies; frequently none for the specific strain |
| Government-reviewed dosing protocol | ✓ Two instructions approved by the Kazakh Ministry of Health Pharmacological Commission | Manufacturer-set dosing |
| Independent compositional analysis | ✓ Antigen Protocol No. FKh/26 (March 2025); ATU Test Report No. 798 (2024) | Rarely published |
| Cross-species field corroboration | ✓ Swine and poultry programmes at scale | Not applicable |
| Randomised, placebo-controlled trial on the current formulation | ✗ Does not yet exist — stated openly as the central evidence gap | Occasionally exists for well-studied strains |
| Modern regulatory clearance (FDA / EMA) | ✗ Not held; the product is a food supplement | Not held |
Two independent Kazakh laboratories have analysed the liquid product. Antigen NPP tested it against national dairy standards in March 2025; Almaty Technological University assayed viable count in 2024.
| Parameter | Result (per 100 ml, liquid) | Method |
|---|---|---|
| Protein | 5.6 g | GOST 30648.2-99 |
| Vitamin C | 67.6 mg (HPLC-DAD) | GOST 34151-2017 |
| Energy value | 32.95 kcal | — |
| Potassium | 362.8 mg | GOST 30178-96 |
| Magnesium | 194.2 mg | GOST 30178-96 |
| Zinc / iron / copper | 0.908 / 0.129 / 0.024 mg | GOST 30178-96 |
| Calcium | 1,825.3 mg as recorded — see the note below | GOST 30178-96 |
| Viable lactic-acid microorganisms | 20 billion CFU; zero coliforms | ATU Test Report No. 798 (Sep 2024) |
Both documents are published in full so that any clinician, retailer or researcher can read the underlying records rather than a summary of them.
Twenty-one pages assembling four decades of microbiological research, institutional clinical records, patents and laboratory protocols. Every claim is tagged by evidence tier, and Section 13 sets out plainly what the record does not establish.
Open the dossier (PDF)
Sixty-eight pages of the underlying archive — the KazNMU journal pages, the 1994 institutional clinical acts, the Ministry-approved clinical-use instructions, patent certificates and veterinary field reports — each reproduced alongside an English translation.
Open the source documents (PDF)
The March 2025 physico-chemical analysis of the liquid product against national dairy standards, including the 67.6 mg/100 ml vitamin C determination by HPLC-DAD.
Read the laboratory section
The patent certificate granted by the Eurasian Patent Office on 29 October 2010, together with the Kazakhstan national patent, the MAKSILIN wordmark registration and the 2012 conformity certificate.
Read the patent sectionPublishing the limits alongside the findings is the whole point of a document trail. The framework below is taken directly from the physician dossier.
| Documented and defensible | Requires qualification | Not substantiated by these documents |
|---|---|---|
| Multi-decade research and institutional-use history | Antibiotic tolerance — the organism survives antibiotic exposure | Treating or curing cancer |
| Strain 2585 lineage, patented in two jurisdictions | Whether the sachet delivers results equivalent to the liquid | Curing serious or systemic infections |
| Human dysbacteriosis microbiological observations (KazNMU) | Practitioner-reported outcomes — observational, not causal | Replacing antibiotics |
| In vitro antagonistic activity under the conditions studied (Pichkhadze et al., 2000) | "First" or "only in the world" phrasing — an unverifiable superlative | Treating COVID-19 or other viral disease |
| Institutional clinical use under Ministry-approved instructions | Historical military use — company narrative, uncorroborated | Broad disease-treatment or universal-effectiveness claims |